A 28-amino-acid immune powerhouse originally from thymus tissue. It strengthens both your fast-response and long-term immune systems: helps immune cells (T-cells) mature, boosts your natural killer cells, and balances your immune response so it's neither too weak nor too aggressive. Tested in over 3,000 patients in clinical trials, approved in 35+ countries, and used for hepatitis B/C, HIV support, cancer treatment support, and serious infections. No serious side effects linked to the peptide.
What to Expect
Week 1–2
Enhanced innate immune surveillance. May notice fewer early cold/flu symptoms. Subtle improvement in energy if immune system was compromised.
Week 3–6
Measurably improved immune function — fewer infections, faster recovery from illness. Enhanced T-cell counts on bloodwork. Improved vaccine response.
Week 8+
Sustained immune optimization. Potential anti-tumor immune surveillance benefits. Improved recovery from chronic infections. Reduced autoimmune flare frequency in some users.
Common Side Effects
Scientific Overview
Thymosin Alpha-1 is a 28-amino acid peptide originally isolated from thymic tissue (Thymosin Fraction 5). It functions as a biological response modifier, enhancing T-cell maturation, dendritic cell function, and natural killer cell activity. TA1 modulates TLR2, TLR5, and TLR9 signaling in dendritic cells and promotes Th1 over Th2 immune responses. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant, with clinical data spanning over 3,000 patients in controlled trials.
Dosing
1.6-2 mg subq once or twice a week. Standard protocol is 1.6 mg twice weekly for 6-12+ months. You can increase frequency if you're fighting off an acute illness. Consistency matters more than timing.
Practical Guide
Reconstitution
Mix 3mg or 5mg vial with 1mL BAC water. Typical dose is 1.6mg (450mcg/kg).
Storage
Refrigerate after reconstitution. Use within 21-30 days.
Injection Sites
Subcutaneous injection with insulin syringe. Rotate sites to prevent lipodystrophy with extended use.
Timing
Morning injection preferred to align with immune system circadian rhythm. Consistent daily timing.
Food
No food interactions.
Benefit Profile
Medical Considerations
Contraindications
- ✕Organ transplant recipients on immunosuppression
- ✕Active autoimmune disease in flare (may exacerbate)
- ✕Pregnancy/nursing
Drug Interactions
Recommended Monitoring
- →CBC with differential
- →T-cell subset panel if immunocompromised
- →Monitor autoimmune markers if history
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis.
The Effect of Ulinastatin on Sepsis Outcomes: An Umbrella Review of Meta-Analysis.
Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis.
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial.
The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.
A Prospective and Randomized Control Study on Effects of Thymalfasin for Injection on Perioperative Immune Function and Long-term Prognosis of Patients with Colorectal Cancer.
A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report.